AZN
HEALTHCAREAstraZeneca PLC
AI Insight
What's Moving AZN Today?
No stock-specific AI insight has been generated for AZN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$134.85$210.50
$168.37
Fundamentals
Market Cap$262.8B
P/E Ratio25.5
EPS$6.64
Dividend Yield1.86%
Dividend / Share$3.20
ROE23.5%
Profit Margin17.2%
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding1.55B
AZN News
73 articles- Panic grips Ionis Pharmaceuticals investors amid bad news spreeThe Street·Jul 12, 2026
- AstraZeneca erases billions after sobering revealThe Street·Jul 12, 2026
- AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center StageMarketbeat·Jul 11, 2026
- Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?Yahoo Finance·Jul 11, 2026
- Astrazeneca (AZN) Stock Dips While Market Gains: Key FactsYahoo Finance·Jul 10, 2026
- Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial FailureYahoo Finance·Jul 10, 2026
- Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?Yahoo Finance·Jul 10, 2026
- How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week HighYahoo Finance·Jul 10, 2026
- Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial FailsYahoo Finance·Jul 10, 2026
- BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?Yahoo Finance·Jul 10, 2026
- AstraZeneca Plunges After New Heart Disease Drug Fails TrialThedailyupside·Jul 10, 2026
- AstraZeneca (LSE:AZN) Misses Key Wainua Trial Goal Beyond OncologyYahoo Finance·Jul 10, 2026
- BridgeBio stock jumps after rival heart drug fails key trialThe Street·Jul 9, 2026
- NeoGenomics (NEO) Stock Trades Up, Here Is WhyYahoo Finance·Jul 9, 2026
- Lumentum, Sandisk, Applied Materials, AstraZeneca, and More Stocks That Explain Today’s MarketYahoo Finance·Jul 9, 2026
- Stocks shrug off tensions to rise on renewed tech interestYahoo Finance·Jul 9, 2026
- Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To JumpYahoo Finance·Jul 9, 2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo Finance·Jul 9, 2026
- Trending: Salesforce stock dips on Keybanc downgrade, AstraZeneca drug trial falls shortYahoo Finance·Jul 9, 2026
- AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage GoalYahoo Finance·Jul 9, 2026
- Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billionReuters·Jul 7, 2026
- AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100GuruFocus·Jul 2, 2026
- China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drugmarketscreener.com·Jul 2, 2026
- AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 TeGuruFocus·Jul 1, 2026
- AstraZeneca Details Bone Health Data For Strensiq SuccessorScrip·Jun 30, 2026
- ASTRAZENECA : Sell rating from Deutsche Bankwww.marketscreener.com·Jun 30, 2026
- AstraZeneca (AZN) officer receives Ordinary Share award under incentive planStock Titan·Jun 17, 2026
- [Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc.·Jun 16, 2026
- EHA26: AstraZeneca battles Roche in untreated follicular lymphomaClinical Trials Arena·Jun 16, 2026
- AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer IndicationYahoo Finance·Jun 16, 2026
- AstraZeneca PLC Stock (AZN) Closed Down by 3.17% on Jun 1: Facts Behind the MovementTradingKey·Jun 1, 2026
- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionThe Motley Fool·May 31, 2026
- AstraZeneca gets FDA nod for new hypertension drug BaxfendyMSN·May 31, 2026
- CelLBxHealth signs master services agreement with AstraZenecaProactive financial news·May 29, 2026
- AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancermarketscreener.com·May 28, 2026
- AstraZeneca (AZN) CEO granted 18,359 shares as performance award vestsStock Titan·May 19, 2026
- FDA approves AstraZeneca’s new kind of hypertension drugBioPharma Dive·May 19, 2026
- AstraZeneca plc stock (GB0009895292): oncology and vaccines stay in focus after latest earnings and pipeline updatesAD HOC NEWS·May 18, 2026
- AstraZeneca (AZN) secures US approval for first-in-class Baxfendy hypertension treatmentStock Titan·May 18, 2026
- Enhertu gains early breast cancer approvals for AstraZeneca (NYSE: AZN) in USStock Titan·May 18, 2026
Price Data
Open$166.22
Previous Close$164.50
Day High$169.58
Day Low$166.21
52 Week High$210.50
52 Week Low$134.85
52-Week Range
$134.85$210.50
$168.37
Fundamentals
Market Cap$262.8B
P/E Ratio25.5
EPS$6.64
Dividend Yield1.86%
Dividend / Share$3.20
ROE23.5%
Profit Margin17.2%
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding1.55B
About AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeCommon Stock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—